ISRCTN83738603已完成2 期
A Phase II pilot safety and tolerability study of ILB in patients with Motor Neurone Disease (MND)/Amyotrophic Lateral Sclerosis (ALS)
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 11
研究概览
简要总结
2024 Results article in https://pubmed.ncbi.nlm.nih.gov/38990927/ (added 15/07/2024)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Patients > = 18 years and who have provided written informed consent to participate in the study
- •2. Prior to trial entry patients will have a definite diagnosis of ALS according to El Escorial Criteria. All patients will demonstrate either:
- •2.1 Presence of UMN (increased tone, brisk reflexes) as well as LMN (weakness, wasting and fasciculation) signs in the bulbar region and at least two of the other spinal regions (cervical, thoracic or lumbosacral) OR
- •2.2 Presence of UMN and LMN signs in all three spinal regions (cervical, thoracic or lumbosacral)
- •3. Electrophysiological tests (Electromyography (EMG) / Nerve Conduction Study (NCS)) that supports the diagnosis of Motor Neurone Disease (MND)
- •4. Forced Vital Capacity (FVC) > = 50% of predicted value for gender, height and age at screening and a mean Sniff Nasal Inspiratory Pressure (SNIP) > = 50% of predicted value for age
- •5. Adequate haematological function (Hb> = 10g/dl), absolute neutrophil count > = 1.5x109/L and a platelet count > = 60 x109/L
- •6. International Normalised Ratio (INR) < = 1.5, aPTT 30 – 40 seconds, PT 11-13.5 seconds
- •7. Patient willing and able to comply with scheduled visits, treatment plan and other study procedures.
- •8. Patients taking Riluzole must have discontinued treatment > = 28 days prior to study entry (and following consent to take part in the study)
- •9. Women Of Child Bearing Potential (WOCBP) who agree to use highly effective means of contraception (as defined in the Heads of Medicines Agencies_Clinical Trials Facilitation Group (HMA_CTFG) guideline for the entirety of the study
排除标准
- •1. Patients classified as either probable or possible ALS according to El Escorial Criteria
- •2. Subjects in whom other causes of neuromuscular weakness have not been excluded.
- •3. Assisted ventilation of any type within 3 months before the screening visit or at screening
- •4. Patients requiring Radiologically Inserted Gastrostomy (RIG) or Percutaneous Endoscopic Gastroscopy (PEG) feeding
- •5. Involvement in any other interventional study involving use of another IMP or biological product within 3 months of screening
- •6. Any use of antioxidants, edaravone, tirasemtiv or CK-2127107 within 1 month before the screening visit.
- •7. Any botulinum toxin use within 3 months before the screening visit
- •8. Any form of stem cell or gene therapy for the treatment of amyotrophic lateral sclerosis (ALS)
- •9. Neuroimaging of brain and cervical spine with Magnetic Resonance Imaging (MRI) indicating compressive myelopathy as an alternate diagnosis
- •10. Laboratory examinations including Acetylcholine receptor (AChR) antibodies and Muscle Specific Kinase (MuSK) antibodies to exclude Bulbar onset Myasthenia gravis from Bulbar onset Motor Neurone disease as an alternate diagnosis and Antinuclear Antibodies (ANA), Anti-neutrophil cytoplasmic antibodies (ANCA), Extractable Nuclear Antigen (ENA) antibodies, Creatine Kinase (CK), electrophoresis and immunoglobulin indicating an alternate diagnosis for muscle disease like Myositis
- •11. Abnormal liver function defined as AST and/or ALT > 3 times upper limit of normal
- •12. Any head trauma, intracranial or spinal surgery within 3 months of trial entry
- •13. Patients who have had recurrent falls will be excluded to reduce the risk of intracerebral haemorrhage with this Investigational Medicinal Product (IMP)
- •14. Current use of an anticoagulant e.g Warfarin, Aspirin, Clopidogrel, any novel anticoagulants (NOAC)s or low molecular weight heparin
- •15. Uncontrolled hypertension
- •16. Current or previous history of heparin-induced thrombocytopenia
- •17. Active peptic ulcer disease
- •18. Known hypersensitivity to sulphur
- •19. Severe liver insufficiency
- •20. Patients with evidence of major psychiatric illness, significant cognitive impairment or clinically evident dementia that may interfere with the patient`s ability to comply with study procedures.
- •21. Pulmonary illness (e.g asthma or Chronic Obstructive Pulmonary Disease (COPD) requiring regular treatment
- •22. Patient judged to be actively suicidal by the Investigator during 3 months before the screening visit
- •23. Subjects with a diagnosis of another neurodegenerative disease (e.g. Parkinson`s disease, Altzheimers disease and Frontotemporal dementia)
研究者
相似试验
已完成
1 期
A Phase I/II study evaluating the safety and activity of pegylated recombinant human arginase (BCT-100) in relapsed/refractory cancers of children and young adultsCancerISRCTN21727048niversity of Birmingham49
进行中（未招募）
Unknown
Timing an intervention for aortic stenosis with remote patient monitoringRemote monitoring of patients with aortic stenosisCirculatory SystemISRCTN19413194niversity of Birmingham66
已完成
Unknown
A clinical trial to find out the optimal oral iron dosing schedule for the prevention of anaemia in pregnant women (PANDA-Dose study)Iron supplementation in pregnant womenPregnancy and ChildbirthISRCTN12911644HS Blood and Transplant300
进行中（未招募）
1 期
A Phase 2a Study to Evaluate Safety, Tolerability, and Efficacy of PRCL-02 in Patients with Moderate to Severe Chronic Plaque PsoriasisPatients with moderate to severe chronic plaque psoriasis.MedDRA version: 20.0Level: LLTClassification code 10071117Term: Plaque psoriasisSystem Organ Class: 100000004858EUCTR2018-001216-29-SKPRCL Research Inc.81
进行中（未招募）
不适用
A Phase IIb study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of ARX201 Following Repeated Dosing to Young Adult Patients with Childhood Onset Growth Hormone Deficiency (GHD)Growth Hormone DeficiencyMedDRA version: 9.1Level: LLTClassification code 10056438Term: Growth hormone deficiencyEUCTR2007-001746-40-HUAmbrx, Inc., USA45